Vanguard Personalized Indexing Management LLC Increases Stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Vanguard Personalized Indexing Management LLC increased its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 16.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,206 shares of the company’s stock after buying an additional 5,170 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $2,759,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in RDY. Trexquant Investment LP purchased a new position in shares of Dr. Reddy’s Laboratories during the fourth quarter valued at $219,000. Assetmark Inc. boosted its position in Dr. Reddy’s Laboratories by 3.2% during the fourth quarter. Assetmark Inc. now owns 47,711 shares of the company’s stock valued at $3,320,000 after purchasing an additional 1,479 shares in the last quarter. Team Hewins LLC bought a new stake in Dr. Reddy’s Laboratories during the fourth quarter valued at about $239,000. Orion Portfolio Solutions LLC boosted its position in Dr. Reddy’s Laboratories by 89.1% during the fourth quarter. Orion Portfolio Solutions LLC now owns 14,532 shares of the company’s stock valued at $1,015,000 after purchasing an additional 6,846 shares in the last quarter. Finally, Parallel Advisors LLC boosted its holdings in Dr. Reddy’s Laboratories by 6.1% in the fourth quarter. Parallel Advisors LLC now owns 6,514 shares of the company’s stock worth $453,000 after acquiring an additional 377 shares in the last quarter. Hedge funds and other institutional investors own 14.02% of the company’s stock.

Analysts Set New Price Targets

Separately, Barclays raised their price target on Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th.

Dr. Reddy’s Laboratories Price Performance

Shares of NYSE RDY opened at $78.52 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.90 and a current ratio of 2.55. The company has a market cap of $13.10 billion, a PE ratio of 19.48, a P/E/G ratio of 1.74 and a beta of 0.55. The business has a 50-day simple moving average of $81.16 and a two-hundred day simple moving average of $75.72. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $63.72 and a fifty-two week high of $84.46.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Saturday, July 27th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.10 by ($0.10). Dr. Reddy’s Laboratories had a return on equity of 20.32% and a net margin of 19.28%. The firm had revenue of $919.80 million during the quarter, compared to analysts’ expectations of $861.68 million. As a group, equities analysts expect that Dr. Reddy’s Laboratories Limited will post 4.11 EPS for the current fiscal year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.